Global Flow Cytometry Market Report and Forecast 2023-2031

The global flow cytometry market value was USD 4.9 billion in 2022, driven by the rising adoption of flow cytometry in clinical and research settings across the globe. The market size is anticipated to grow at a CAGR of 7.8% during the forecast period of 2023-2031 to achieve a value of USD 9.6 billion by 2031.

Flow Cytometry Introduction

Flow cytometry is a powerful and versatile technology used for the analysis and sorting of cells and particles in suspension, based on their physical and chemical properties. By employing a combination of fluid dynamics, lasers, and detectors, flow cytometry enables the rapid and high-throughput analysis of multiple cellular parameters simultaneously. This technique has become an indispensable tool in various fields of biomedical research, clinical diagnostics, and drug discovery, with applications ranging from immunophenotyping and cell cycle analysis to the detection of rare cell populations and biomarkers.

Flow Cytometry Market Scenario

The global flow cytometry market has experienced significant growth in recent years, driven by advancements in technology, increasing demand for precision medicine, and the growing adoption of flow cytometry in clinical and research settings. Key market players are continuously developing innovative instruments, reagents, and software solutions to address the evolving needs of researchers and clinicians, making flow cytometry more accessible, efficient, and accurate.

The adoption of flow cytometry has been steadily increasing across various segments of biomedical research, clinical diagnostics, and pharmaceutical industries. Factors such as the growing prevalence of chronic diseases, advancements in flow cytometry technology, and an increasing focus on precision medicine have contributed to the widespread adoption of flow cytometry.

North America: The largest market for flow cytometry, driven by factors such as advanced healthcare infrastructure, a strong focus on research and innovation, and widespread adoption of flow cytometry in clinical and research settings.

Europe: The second-largest market, with strong investments in research and development, and a growing demand for precision medicine and advanced diagnostic tools.

Asia-Pacific: Expected to witness the highest growth rate due to factors such as increasing healthcare expenditure, growing awareness of advanced diagnostic technologies, and rising investments in biomedical research.

Flow Cytometry Market Segmentations

Market Breakup by Components

Platforms
Instrument’s
Sorters

Replaceable Components

Filters
Lasers
Detectors
Others

Reagents and Consumables

Antibodies
Dyes
Beads
Others
Software
Services

Market Breakup by Technology

Cell Based Flow Cytometry
Bead Based Flow Cytometry

Market Breakup by Application

Research

Pharmaceuticals
Drug Discovery
In Vitro Toxicity
Stem Cell
Apoptosis
Cell Sorting
Cell Cycle Analysis
Immunology
Cell Viability
Industrial

Clinical

Cancer
Organ Transplantation
Immunodeficiency
Hematology

Market Breakup by End User

Hospitals
Research Labs
Pharmaceuticals & Biotechnology Companies
Academic & Research Institutes
Clinical Testing Laboratories
Blood bank
Others

Market Breakup by Region

North America

United States of America
Canada

Europe

United Kingdom
Germany
France
Italy
Others

Asia Pacific

China
Japan
India
ASEAN
Australia
Others

Latin America

Brazil
Argentina
Mexico
Others

Middle East and Africa

Saudi Arabia
United Arab Emirates
Nigeria
South Africa
Others

Key Trends in the Flow Cytometry Market

Some of the key trends in the market are as follows:

Technological advancements: The development of new flow cytometry instruments, reagents, and software has led to increased sensitivity, resolution, and throughput, enabling researchers to obtain more accurate and detailed information from their samples
Multiparameter analysis: The ability to analyze multiple cellular parameters simultaneously has expanded the scope and applications of flow cytometry, making it a powerful tool for research and diagnostics
Integration with other technologies: The integration of flow cytometry with other analytical techniques, such as mass spectrometry and imaging, has created new opportunities for multiplexed analysis and in-depth characterization of cells and particles
Expansion into emerging markets: The flow cytometry market is expanding into emerging markets, such as Asia-Pacific and Latin America, due to increasing investments in healthcare infrastructure and growing demand for advanced diagnostic technologies

Flow Cytometry Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Agilent Technologies, Inc
BD, Bio-Rad Laboratories, Inc
Beckman Coulter, Inc
Luminex Corporation
Sony Biotechnology Inc
Apogee Flow Systems Ltd
Cytek Biosciences
bioMérieux SA
Merck KGaA
Elabscience Biotechnology Inc
Miltenyi Biotec
Takara Bio Inc
Thermo Fisher Scientific Inc
CellKraft Biotech Pvt. Ltd
Sartorius AG
NeoGenomics Laboratories
Bay bioscience Co., Ltd
Cell Signaling Technology, Inc
CytoBuoy b.v.,
ORFLO Technologies
IKEDA SCIENTIFIC Co., Ltd
BioLegend, Inc., II-VI Incorporated
Enzo Biochem Inc
Union Biometrica, Inc
Cytonome/ST, LLC, Stratedigm, Inc
NanoCellect Biomedical
BennuBio Inc
Nexcelom Bioscience LLC
On-chip Biotechnologies Co., Ltd. Corporation
Enzo Biochem Inc

Frequently Asked Questions about the Global Flow Cytometry Market

What is the estimated value of the Global Flow Cytometry Market?

The Global Flow Cytometry Market was estimated to be valued at $5.29 Billion in 2023.

What is the growth rate of the Global Flow Cytometry Market?

The growth rate of the Global Flow Cytometry Market is 7.8%, with an estimated value of $9.62 Billion by 2031.

What is the forecasted size of the Global Flow Cytometry Market?

The Global Flow Cytometry Market is estimated to be worth $9.62 Billion by 2031.

Who are the key companies in the Global Flow Cytometry Market?

Key companies in the Global Flow Cytometry Market include Agilent Technologies, Inc., Bd, Bio, Rad Laboratories, Inc., Beckman Coulter, Inc., Luminex Corporation, Sony Biotechnology Inc., Apogee Flow Systems Ltd., Cytek Biosciences, Biomérieux Sa and Merck Kgaa.

Report Attribute	Details
No. of Pages	140
Published	May 2023
Forecast Period	2023 - 2031
Estimated Market Value ( USD ) in 2023	$ 5.29 Billion
Forecasted Market Value ( USD ) by 2031	$ 9.62 Billion
Compound Annual Growth Rate	7.8%
Regions Covered	Global
No. of Companies Mentioned	30

1 Preface

1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology

2 Executive Summary

3 Global Flow Cytometry Market Overview

3.1 Global Flow Cytometry Market Historical Value (2016-2022)
3.2 Global Flow Cytometry Market Forecast Value (2023-2031)

4 Global Flow Cytometry Market Landscape

4.1 Global Flow Cytometry Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Flow Cytometry Product Landscape
4.2.1 Analysis by Component
4.2.2 Analysis by Technology
4.2.3 Analysis by Applications

5 Global Flow Cytometry Market Dynamics

5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis

6 Global Flow Cytometry Market Segmentation

6.1 Global Flow Cytometry Market by Components
6.1.1 Market Overview
6.1.2 Platforms
6.1.3 Instrument’s
6.1.4 Sorters
6.1.5 Replaceable Components
6.1.5.1 Filters
6.1.5.2 Lasers
6.1.5.3 Detectors
6.1.5.4 Others
6.1.6 Reagents and Consumables
6.1.6.1 Antibodies
6.1.6.2 Dyes
6.1.6.3 Beads
6.1.6.4 Others
6.1.7 Software
6.1.8 Services
6.2 Global Flow Cytometry Market by Technology
6.2.1 Market Overview
6.2.2 Cell Based Flow Cytometry
6.2.3 Bead Based Flow Cytometry
6.3 Global Flow Cytometry Market by Application
6.3.1 Market Overview
6.3.2 Research
6.3.2.1 Pharmaceuticals
6.3.2.2 Drug Discovery
6.3.2.3 In Vitro Toxicity
6.3.2.4 Stem Cell
6.3.2.5 Apoptosis
6.3.2.6 Cell Sorting
6.3.2.7 Cell Cycle Analysis
6.3.2.8 Immunology
6.3.2.9 Cell Viability
6.3.3 Industrial
6.3.4 Clinical
6.3.4.1 Cancer
6.3.4.2 Organ Transplantation
6.3.4.3 Immunodeficiency
6.3.4.4 Hematology
6.4 Global Flow Cytometry Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Research Labs
6.4.4 Pharmaceuticals & Biotechnology Companies
6.4.5 Academic & Research Institutes
6.4.6 Clinical Testing Laboratories
6.4.7 Blood bank
6.4.8 Others
6.5 Global Flow Cytometry Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa

7 North America Flow Cytometry Market

7.1 Market Share by Country
7.2 United States of America
7.3 Canada

8 Europe Flow Cytometry Market

8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others

9 Asia Pacific Flow Cytometry Market

9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others

10 Latin America Flow Cytometry Market

10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others

11 Middle East and Africa Flow Cytometry Market

11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others

12 Patent Analysis

12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players

13 Grants Analysis

13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization

14 Funding Analysis

14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography

15 Partnership and Collaborations Analysis

15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography

16 Regulatory Framework

16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others

17 Supplier Landscape

17.1 Agilent Technologies, Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 BD, Bio-Rad Laboratories, Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Beckman Coulter, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Luminex Corporation
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Sony Biotechnology Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Apogee Flow Systems Ltd.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Cytek Biosciences
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 bioMérieux SA
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Merck KGaA
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Elabscience Biotechnology Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Miltenyi Biotec
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Takara Bio Inc.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Thermo Fisher Scientific Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 CellKraft Biotech Pvt. Ltd.
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Sartorius AG
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 NeoGenomics Laboratories
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
17.17 Bay bioscience Co., Ltd.
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
17.17.5 Certifications
17.18 Cell Signaling Technology, Inc.
17.18.1 Financial Analysis
17.18.2 Product Portfolio
17.18.3 Demographic Reach and Achievements
17.18.4 Mergers and Acquisitions
17.18.5 Certifications
17.19 CytoBuoy b.v.,
17.19.1 Financial Analysis
17.19.2 Product Portfolio
17.19.3 Demographic Reach and Achievements
17.19.4 Mergers and Acquisitions
17.19.5 Certifications
17.20 ORFLO Technologies
17.20.1 Financial Analysis
17.20.2 Product Portfolio
17.20.3 Demographic Reach and Achievements
17.20.4 Mergers and Acquisitions
17.20.5 Certifications
17.21 IKEDA SCIENTIFIC Co., Ltd.
17.21.1 Financial Analysis
17.21.2 Product Portfolio
17.21.3 Demographic Reach and Achievements
17.21.4 Mergers and Acquisitions
17.21.5 Certifications
17.22 BioLegend, Inc., II-VI Incorporated
17.22.1 Financial Analysis
17.22.2 Product Portfolio
17.22.3 Demographic Reach and Achievements
17.22.4 Mergers and Acquisitions
17.22.5 Certifications
17.23 Enzo Biochem Inc.
17.23.1 Financial Analysis
17.23.2 Product Portfolio
17.23.3 Demographic Reach and Achievements
17.23.4 Mergers and Acquisitions
17.23.5 Certifications
17.24 Union Biometrica, Inc.
17.24.1 Financial Analysis
17.24.2 Product Portfolio
17.24.3 Demographic Reach and Achievements
17.24.4 Mergers and Acquisitions
17.24.5 Certifications
17.25 Cytonome/ST, LLC, Stratedigm, Inc
17.25.1 Financial Analysis
17.25.2 Product Portfolio
17.25.3 Demographic Reach and Achievements
17.25.4 Mergers and Acquisitions
17.25.5 Certifications
17.26 NanoCellect Biomedical
17.26.1 Financial Analysis
17.26.2 Product Portfolio
17.26.3 Demographic Reach and Achievements
17.26.4 Mergers and Acquisitions
17.26.5 Certifications
17.27 BennuBio Inc.
17.27.1 Financial Analysis
17.27.2 Product Portfolio
17.27.3 Demographic Reach and Achievements
17.27.4 Mergers and Acquisitions
17.27.5 Certifications
17.28 Nexcelom Bioscience LLC
17.28.1 Financial Analysis
17.28.2 Product Portfolio
17.28.3 Demographic Reach and Achievements
17.28.4 Mergers and Acquisitions
17.28.5 Certifications
17.29 On-chip Biotechnologies Co., Ltd. Corporation
17.29.1 Financial Analysis
17.29.2 Product Portfolio
17.29.3 Demographic Reach and Achievements
17.29.4 Mergers and Acquisitions
17.29.5 Certifications
17.30 Enzo Biochem Inc.
17.30.1 Financial Analysis
17.30.2 Product Portfolio
17.30.3 Demographic Reach and Achievements
17.30.4 Mergers and Acquisitions
17.30.5 Certifications

18 Global Flow Cytometry Distribution Model (Additional Insight)

18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment

19 Key Opinion Leaders (KOL) Insights (Additional Insight)

20 Company Competitiveness Analysis (Additional Insight)

20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies

21 Payment Methods (Additional Insight)

21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket